Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 15,000 Shares

Moderna, Inc. (NASDAQ:MRNAGet Free Report) President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $112.99, for a total transaction of $1,694,850.00. Following the sale, the president now owns 1,574,187 shares of the company’s stock, valued at $177,867,389.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Stephen Hoge also recently made the following trade(s):

  • On Tuesday, August 29th, Stephen Hoge sold 1,135 shares of Moderna stock. The stock was sold at an average price of $115.01, for a total transaction of $130,536.35.
  • On Thursday, August 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00.
  • On Thursday, August 10th, Stephen Hoge sold 247 shares of Moderna stock. The stock was sold at an average price of $102.53, for a total value of $25,324.91.
  • On Monday, July 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $120.60, for a total value of $1,809,000.00.

Moderna Trading Down 9.1 %

Shares of MRNA stock opened at $104.14 on Tuesday. Moderna, Inc. has a 1 year low of $95.02 and a 1 year high of $217.25. The firm’s fifty day simple moving average is $112.49 and its 200 day simple moving average is $127.70. The firm has a market capitalization of $39.63 billion, a P/E ratio of 38.43 and a beta of 1.63. The company has a current ratio of 3.39, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNAGet Free Report) last announced its earnings results on Thursday, August 3rd. The company reported ($3.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.84) by $0.22. The business had revenue of $344.00 million for the quarter, compared to analyst estimates of $307.67 million. Moderna had a net margin of 11.33% and a return on equity of 6.62%. Moderna’s revenue was down 92.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.24 earnings per share. As a group, sell-side analysts predict that Moderna, Inc. will post -4.31 EPS for the current year.

Analyst Ratings Changes

MRNA has been the topic of several recent research reports. HSBC began coverage on shares of Moderna in a research report on Friday, July 14th. They set a “reduce” rating and a $97.00 price objective on the stock. UBS Group upgraded shares of Moderna from a “neutral” rating to a “buy” rating and cut their price target for the company from $221.00 to $191.00 in a report on Monday, June 26th. Morgan Stanley cut their price target on shares of Moderna from $128.00 to $123.00 and set an “equal weight” rating on the stock in a report on Friday, August 4th. Jefferies Financial Group cut their price target on shares of Moderna from $275.00 to $175.00 in a report on Friday, August 4th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Moderna from a “buy” rating to a “hold” rating and cut their price target for the company from $200.00 to $125.00 in a report on Thursday, August 3rd. Three analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $155.52.

Check Out Our Latest Report on Moderna

Hedge Funds Weigh In On Moderna

Several large investors have recently added to or reduced their stakes in the company. ICA Group Wealth Management LLC bought a new position in shares of Moderna during the 4th quarter worth about $27,000. GHP Investment Advisors Inc. lifted its holdings in shares of Moderna by 208.3% during the 1st quarter. GHP Investment Advisors Inc. now owns 185 shares of the company’s stock worth $28,000 after acquiring an additional 125 shares during the period. Heritage Wealth Management LLC lifted its holdings in shares of Moderna by 100.0% during the 4th quarter. Heritage Wealth Management LLC now owns 226 shares of the company’s stock worth $41,000 after acquiring an additional 113 shares during the period. Stone House Investment Management LLC acquired a new stake in Moderna in the 1st quarter valued at $36,000. Finally, Close Asset Management Ltd boosted its stake in Moderna by 1,250.0% in the 2nd quarter. Close Asset Management Ltd now owns 270 shares of the company’s stock valued at $33,000 after buying an additional 250 shares in the last quarter. Institutional investors and hedge funds own 64.51% of the company’s stock.

About Moderna

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.